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Proteinase K-resistant prion protein (PrPRes) nuclear and
perinuclear immunoreactivity in oligodendrocytes of the
frontal cortex is found in one case of otherwise typical
sporadic Creutzfeldt-Jakob disease (sCJD) type VV2a.
The PrP nature of the inclusions is validated with several
anti-PrP antibodies directed to amino acids 130–160
(12F10), 109–112 (3F4), 97–102 (8G8) and the octarepeat
region (amino acids 59–89: SAF32). Cellular identification
and subcellular localization were evaluated with double-
and triple-labeling immunofluorescence and confocal
microscopy using antibodies against PrP, glial markers,
and histone H3. Based on review of the literature and our
own experience, this is a very odd situation that deserves
further validation in other cases.
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INTRODUCTION
Prion diseases are a group of transmissible encephalopa-
thies linked to cellular prion protein (PrPC) which is
converted into an abnormally conformed proteinase K-
resistant prion protein (PrPRes). The human prion diseases
are sporadic, iatrogenic or genetic Creutzfeld–Jakob dis-
ease (sCJD, iCJD and gCJD, respectively), variant CJD,
Gerstmann-Straüsler-Scheinker disease (GSS), and fatal
familial insomnia (FFI); gCJD, GSS, and FFI are due to
mutations in the PPNP gene (PPNP)1–5
sCJD is characterized clinically by rapid dementia
accompanied by other neurological symptoms, and neu-
ropathologically by neuronal loss, spongiform change,
astrocytosis, microgliosis, and PrPRes deposition.4,5 Several
PrP types (types I and II, and variants) are recognized
depending on the pattern of mono-glycosylated, di-glyco-
sylated, and non-glycosylated prion.6,7 In addition, codon
129 (methionine or valine) in PRNP is largely contribu-
tory to clinical and neuropathological phenotypes.4,5
Moreover, PrP types correlate with characteristic PrPRes
deposits in tissue sections.8
PrPRes deposits have particular patterns including dif-
fuse/synaptic, patchy/perivacuolar, perineuronal, plaque-
like, and kuru-like plaques, largely depending on the sCJD
subtype.4,5,9 In addition, punctuate intracytoplasmic neuro-
nal deposits, rows of PrPRes deposits along myelinated
fibers, and rare intracytoplasmic PrPRes-positive granules
in astrocytes and microglia are reported in CJD and other
prionopathies.5,9–13
The present report describes unique abundant
intracytoplasmic PrPRes nuclear and perinuclear immuno-
reactivity in astrocytes and oligodendrocytes in one case
of sCJD VV2.
CASE PRESENTATION
A 66-year-old man had suffered from gait ataxia, cognitive
impairment, sleeping difficulties, and myoclonus for the
previous two months. There was no family history of neu-
rological disease. Cerebrospinal fluid test was positive for
14-3-3 protein. EEG showed slow waves with periodic
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synchronous discharges. Extensive cortical ribbon-like,
basal ganglia, and cerebellum hyper-signals were noted on
magnetic resonance imaging (MRI) examination. Progres-
sion of the disease was to a vegetative state. The patient
died of bronchopneumonia four and a half months after
clinical onset.
PATHOLOGICAL EXAMINATION
The brain weight was 1400 g. The left cerebral hemisphere
was rapidly frozen and stored at −80C for biochemical
studies. Gross examination of the right cerebral hemisphere
after 4% buffered formalin fixation revealed severe atrophy
of the cerebellum, mainly involving the vermis, and the
presence of a lacunar infarct in the internal capsule. Ante-
mortem factors including agonal state, hypoxia, acidosis,
fever, seizures, and medication were ruled out. Post-mortem
factors were within normal limits. Post-mortem delay (inter-
val between death and sample processing) was around 5 h
and the duration of fixation was up to 3 weeks.
Microscopic examination revealed widespread micro-
vacuoles (spongiform changes), mainly in the frontal and
temporal cortex, with a laminar pattern involving the deep
layers, hippocampus, striatum and thalamus, and the molec-
ular layer of the cerebellum. Neuronal loss was found in all
these regions and it was very marked in the cerebellum,
affecting Purkinje cells and neurons of the granular layer;
scattered axonal torpedoes were also observed in the gran-
ular layer. This was accompanied by marked astrocytosis
and severe microgliosis. The cerebral white matter was nor-
mal. Neuronal loss and astrocytosis occurred in the mid-
brain, and spongiform change was also observed in the
pons. Immunohistochemistry with the 3F4 anti-PrP mouse
monoclonal antibody (1:200; Millipore, Billerica, MA,
USA) following proteinase K incubation (100 μg/mL; 37C;
1 h) and 10% formic acid for 1 h showed synaptic-like and
frequent small granular plaque-like PrPRes deposits, and
perineuronal deposits in the neocortex and basal ganglia.
Plaque-like PrPRes deposits were abundant in the cerebellar
cortex and white matter; synaptic-like PrPRes immunoreac-
tivity was present in the molecular layer as well. Small
PrPRes-immunoreactive dots (between 0.2 and 1.0 μm) were
present in the perikaryon of several neurons. In addition,
PrPRes nuclear (perinuclear) immunoreactivity was noted,
apparently in the vicinity of, or within, glial nuclei in the
frontal, parietal and temporal cortex. For PrPRes identifica-
tion of glial deposits, immunohistochemistry was performed
using specific antibodies recognizing different PrP epitopes,
conducted on 4-μm-thick paraffin sections following a pro-
tocol reported elsewhere.11 To summarize, sections were
first exposed to a combined pretreatment including
hydrated autoclaving with 3 mM HCL acid (Merck,
Kenilworth, NJ, USA) in distilled water incubated for
2 min after boiling, followed by 5 min incubation in 96%
formic acid (Merck, Madrid, Spain) at room temperature.
After washing, sections were incubated with serial protein-
ase K (PK) concentrations: 5, 10 and 20 μg/mL for 15 min
at 37C, and were further blocked with Dako Real Peroxi-
dase blocking solution (S2023, Dako, Barcelona, Spain).
Sections were incubated overnight at 4C with the primary
antibodies, diluted in Dako Real Antibody Diluent (S2022,
Dako) (Table 1). Afterwards, sections were incubated with
MultiLink biotinylated antibody followed by horseradish
peroxidase-conjugated streptavidin (QP9009L-E BioGenex
detection kit, Fremont, CA, USA). Immunodetection was
obtained after incubation with 3,30-diaminobenzidine tetra-
hydrochloride (DAB) (D6737; Merck) and H2O2. Sections
were examined with a Nikon Eclipse E800 microscope with
ProgRes® CapturePro 2.7.7 software (JENOPTIK, Jena,
Germany). The results obtained using two additional anti-
PrP antibodies, clones 12F10 and scrapie-associated fibril
32 (SAF32), were similar in the two assays (Fig. 1). Nuclear
(perinuclear) immunoreactivity was not stained with anti-
ubiquitin antibodies. No deposits of amyloid-β, hyper-
phosphorylated tau, α-synuclein, or transactivation response
DNA-binding protein 43 kDa were observed.
Genetic studies revealed no mutation in PRNP and
valine homozygosity at codon 129. Western blotting with
the antibody 3F4 (Dako) at a dilution of 1:3000 revealed a
type II PrPRes pattern; no bands of low molecular weight
were present with this antibody.
In order to identify the characteristics and localization
of PrPSc glial nuclear (perinuclear) immunoreactivity,
Table 1 Summary of antibodies used
Abbreviation Name Company Ref. no. Dilution Target
12F10 Anti-PrP Clone 12F10 SPI-Bio A03221 1:100 Region 130–160
3F4 Anti-PrP Clone 3F4 Millipore MAB1562 1:100 Region 109–112
8G8 Anti-PrP Clone 8G8 SPI-Bio A03220 1:50 Region 97–102
SAF32 Anti-PrP Clone SAF32 SPI-Bio A03202 1:50 Region 59–89
Anti-GFAP Anti-glial fibrillary acidic protein Dako Z0334 1:400 Astrocytes
Anti-H3 Anti-histone H3 Novus NB100-747 1:50 Nuclei
Anti-Iba1 Anti-ionized calcium-binding adaptor molecule 1 Wako 019-19741 1:1000 Microglia
Anti-YKL40 Anti-chitinase-3-like protein 1 (CHI3L1) Thermo-Fisher PA5-43746 1:100 Astrocytes
Olig 2 Anti-oligodendrocyte transcription factor 2 Abcam AB42453 1:500 Oligodendrocytes
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double- and triple-labeling immunofluorescence using spe-
cific neuronal and glial cell antibodies, and antibodies
recognizing different PrP epitopes, was carried out in 4-
μm-thick de-waxed paraffin sections of the frontal cortex.
Sections were first subjected to combined pretreatment11
for PrP staining and then boiled in 10 mmol/L citrate
buffer for 20 min. Sections were subsequently stained with
a saturated solution of Sudan black B (Merck) for 15 min
to block autofluorescence of lipofuscin granules, and then
rinsed in 70% ethanol and washed in distilled water.
Afterwards, sections were blocked with 10% fetal bovine
serum (FBS) for 1 h at room temperature, and incubated
overnight at 4C with appropriate diluted primary anti-
bodies (Table 1). After washing, sections were incubated
with Alexa-Fluor 488, 555, or 647 conjugated secondary
antibodies (Molecular Probes, Eugene, OR, Life Technol-
ogies, Carlsbad, CA, Thermo Fisher Scientific Inc., Wal-
tham, MA, USA, respectively). The sections were
mounted in Immuno-Fluore mounting medium (ICN Bio-
medicals, Irvine, CA, USA), sealed, and dried overnight.
Fig. 1 Histological (H&E; hematoxylin-
eosin) (A-C) and immunohistochemical
(D-I) observations of the brain. (A)
Neuronal loss, spongiform change, and
astrocytosis in the frontal cortex. (B)
Spongiform change and loss of Purkinje
cells in the cerebellum. (C) Spongiform
change and astrocytosis in the Purkinje
cell layer and inner molecular layer. (D)
Synapse-like and granular proteinase K-
resistant prion protein (PrPRES) aggre-
gates in the cerebral cortex. (E) Peri-
neuronal positive immunostaining for
PrPRES. (F) Neuronal positive immuno-
staining for PrPRES. (G) Neuronal posi-
tive immunostaining for PrPRES. (H)
Nuclear and perinuclear positive immu-
nostaining for PrPC in the frontal cortex.
(I) Nuclear and perinuclear positive
immunostaining for PrPRES in the frontal
cortex following proteinase K incubation
for 20 min. Formalin-fixed, paraffin-
embedded sections treated with formic
acid. Scale bars: 40 μm (A), 85 μm (B),
25 μm (C–I).
Fig. 2 Microphotographs by double-
labeling immunofluorescence and confocal
microscopy (A) and quantitative analysis
of PrP antigens, microglial (αIba1), astro-
cytic (αGFAP) and oligodendrocytic
(Olig2) markers (B). (A) Nuclear and
perinuclear areas of astrocytes (αGFAP)
and oligodendrocytes (Olig2) are immuno-
reactive for PrP (3F4) and scrapie-associ-
ated PrP (SAF32). In contrast, there is no
correlation between PrP (SAF32) and
microglia (αIba1). Formalin-fixed, paraf-
fin-embedded sections. Scale bars: 20 μm.
(B) The percentage of PrP (SAF32)-
immunoreactive cells colocalized in oligo-
dendrocytes is significantly higher than in
astrocytes and oligodendrocytes. Results
are mean  SD of 2-3 sections. One-way
analysis of variance shows significant dif-
ference (P < 0.001) of %SAF32 col-
ocalized with the cell markers. Turkey’s
post hoc analysis reveals significant differ-
ence of %SAF32 with Olig2 with respect
to %SAF32 colocalized with antibodies to
Iba1 and GFAP (***P < 0.001).
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Sections were examined with a Leica TCS-SL confocal
microscope and analyzed for co-localization with Image J
1.8.0_112 using JACOP plugin (for Pearson’s coefficient)
and double-staining co-localization macros.
Double-labeling immunofluorescence to glial fibrillary
acidic protein (GFAP) and PrP (3F4 antibody) showed sig-
nificant PrP immunoreactivity in the vicinity of GFAP
fibrils (Fig. 2A, upper row). Yet double-labeling with anti-
oligodendrocyte transcription factor 2 antibody (Olig2) and
SAF32 clearly showed PrP localization in the perinuclear
region and within the nucleus of oligodendrocytes (Fig. 2A,
middle row). No relationship was found between microglia
identified with antibody to ionized calcium-binding adaptor
molecule 1 (Iba1) and PrP deposits (Fig. 2A, lower row).
Quantification of the percentage of cell markers with the
PrP marker showed significant increase only in the %Olig2
that co-localized with %SAF32 (Fig. 2B). Moreover,
Pearson’s coefficient disclosed only a strong positive corre-
lation between Olig2 and SAF32 (Table 2).
Similar PrP immunostaining was obtained with differ-
ent anti-PrP antibodies directed to amino acids 130–160
(12F10), 109–112 (3F4), 97–102 (8G8), and the octarepeat
region (amino acids 59–89: SAF32) as seen by double-
labeling immunofluorescence to GFAP and PrP (Fig. 3).
Triple-labeling with distinct cellular markers, PrP anti-
bodies, and anti-histone H3 revealed that most PrP immu-
noreactivity was localized within the nucleus or in the
perinuclear region of oligodendrocytes, and rarely in astro-
cytes, including subpopulations of YKL40-immunoreactive
astrocytes (Fig. 4). Pearson’s coefficient showed a strong
positive correlation of 12F10 with YKL40, Olig2, and cellu-
lar nuclei (Table 2).
DISCUSSION
Clinical symptoms, neuroimaging, genetics, neuropatho-
logical findings, and Western blot pattern of PrPRes are
typical of sCJD VV2a.4,5,8 Regarding PrPRes deposition,
synaptic-like and small granular plaque-like PrPRes
deposits, and perineuronal deposits in the neocortex and
basal ganglia, together with plaque-like PrPRes deposits in
the cerebellar cortex and white matter, and synaptic-like
PrPRes immunoreactivity in the molecular layer in the pre-
sent case, are consistent with sCJD VV2.5 In addition,
punctate intraneuronal PrP immunoreactivity, here
described as small PrPres-immunoreactive dots in the peri-
karyon, has been observed in scrapie, in experimental
models of prion disease, and rarely, in sCJD.12–15
Rare intra-cytoplasmic PrPRes granules in human and
animal prion diseases have been reported in microglia and
astrocytes, suggesting that both cells may play a role in the
processing, degradation and removal of PrPRes.16,17 PrPRes
microsphere formation in the neuropil has been described
in a rare case of familial CJD.18 However, nuclear and



































Fig. 3 Microphotographs by double-labeling immunofluorescence
and confocal microscopy using antibodies to GFAP and different
PrP antigens (12F10, 3F4, 8G8 and SAF32) showing a close rela-
tionship between nuclear and perinuclear immunoreactivity and
astrocytes (arrows). Formalin-fixed, paraffin-embedded sections.
Scale bars: 20 μm (upper and lower rows), 10 μm (middle rows).
© 2018 Japanese Society of Neuropathology
4 I Fernández-Vega et al.
perinuclear immunoreactivity in cortical astrocytes and oli-
godendrocytes as observed here have not been previously
reported to our knowledge.
The PrP nature of these deposits is supported by the rec-
ognition of similar staining using different anti-PrP anti-
bodies directed against different epitopes of the prion
protein, including 12F10 (amino acids 130–160), 3F4 (amino
acids 109–112), 8G8 (amino acids 97–102), and SAF32
(amino acids 59–89).
PrP immunoreactivity in the inclusions is mostly PK-
resistant; PrP immunoreactivity is maintained at PK con-
centrations of 20 μg/mL. Double- and triple-labeling of
PrP with different neuronal and glial cell markers, and his-
tone H3, clearly demonstrates the glial localization of PrP
immunoreactivity mainly in the nucleus and perinuclear
region in oligodendrocytes.
PrPC is normally expressed in neurons, astrocytes, and
oligodendrocytes during development and adulthood.19
Functions of PrPC during development include modulation
of the differentiation of human stem cells into neurons,
astrocytes, and oligodendrocytes.20,21 Therefore, the PrP
deposits here observed in glial cells are probably produced
in the same cells. How the conversion of PrPC into PrPRes
is produced in oligodendrocytes is not known, as oligoden-
drocytes are apparently resistant to PrPRes infectivity.22
The nuclear localization of glial PrP immunoreactivity is
curious. However, nuclear localization of normal and abnor-
mal PrP has been reported in various settings. Abnormal
transport of C-terminally truncated and abnormally glyco-
sylated mutant PrP to the nucleus has been reported in cell
models of familial prion disorders associated with a stop
codon mutation at residues 145 or 160 of the PrP.23 The N-
terminal region of human and ovine PrP has been described
as harboring nucleic acid binding and chaperoning proper-
ties.24 When acting together, two independent nuclear locali-
zation signals in the N-terminal domain of PrP complement
each other in transporting the N-terminal fragment of PrP to
the nucleus of transfected cells, where it accumulates.25
In addition to truncated forms, PrPC can localize in the
nucleus of different cell types including neural cells, and it
interacts with structural chromatin components, principally
histone H3; the interaction of PrPC with histone H3 sug-
gests that PrP is involved in transcriptional regulation in
the nucleus.26,27 Nuclear PrP interacts with distinct pro-
teins involved in cell proliferation and cell junction in sev-
eral cell types,28 and PrP participates in the process of
DNA repair after genotoxic stress.29
It may be argued that the PrP immunostaining here
observed is not simply up-regulation of PrP for any reason.
However, we have spent many years studying hundreds of
brains with CJD using similar methodological procedures and
the same routine protocols, and have never before observed
those intriguing inclusions. The present findings in a single
case must be corroborated in additional cases to prove that,
although rarely, PrPRes can be localized in the cytoplasm and
nucleus of glial cells, mainly oligodendrocytes, in CJD.
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Fig. 4 Microphotographs by triple-label-
ing immunofluorescence and confocal
microscopy using anti-GFAP, anti-YKL-
40, Olig2, 12F10, and anti-histone H3.
PrP immunoreactivity localizes in the
nucleus of astrocytes and oligodendro-
cytes (arrows). Formalin-fixed, paraffin-
embedded sections. Scale bars: 20 μm.
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